BioCryst Pharmaceuticals Inc.
BCRX | NASDAQ
$8.76
+$0.08 (+0.92%)
At close: Sep 21, 2026, 4:00 PM ET
$8.77
+$0.01 (+0.11%)
Pre-market:
Sep 22, 2026, 9:27 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 874.84M | 450.71M | 331.41M | 270.83M | 157.17M | 17.81M |
Cost of Revenue | 19.08M | 12.49M | 4.66M | 6.59M | 7.26M | 1.68M |
Gross Profit | 855.76M | 438.23M | 326.75M | 264.23M | 149.91M | 16.14M |
Operating Income | 340.99M | -2.54M | -103.71M | -148.44M | -177.72M | -174.76M |
Interest Income | 10.67M | 14.75M | 15.78M | 5.13M | 62K | 9.42M |
Pretax Income | 267.39M | -86.95M | -226.23M | -244.38M | -181.81M | -182.81M |
Net Income | 263.86M | -88.88M | -226.54M | -247.12M | -184.06M | -182.81M |
Selling & General & Admin | 348.65M | 266.13M | 213.89M | 159.37M | 118.82M | 67.93M |
Research & Development | 166.13M | 174.64M | 216.57M | 253.3M | 208.81M | 122.96M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 514.77M | 440.77M | 430.46M | 412.67M | 327.63M | 190.89M |
Interest Expense | 78.87M | 98.52M | 108.24M | 99.09M | 59.29M | 14.5M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 533.85M | 453.26M | 435.12M | 419.26M | 334.89M | 192.57M |
Income Tax Expense | 3.53M | 1.93M | 310K | 2.73M | 2.25M | n/a |
Shares Outstanding (Basic) | 209.89M | 206.7M | 192.2M | 185.91M | 179.12M | 167.27M |
Shares Outstanding (Diluted) | 218.58M | 206.7M | 192.2M | 185.91M | 179.12M | 167.27M |
EPS (Basic) | 1.26 | -0.43 | -1.18 | -1.33 | -1.03 | -1.09 |
EPS (Diluted) | 1.21 | -0.43 | -1.18 | -1.33 | -1.03 | -1.09 |
EBITDA | 347.65M | 12.81M | -116.34M | -143.85M | -121.74M | -167.57M |
EBIT | 346.26M | 11.56M | -117.99M | -145.29M | -122.52M | -168.31M |
Depreciation & Amortization | 1.39M | 1.25M | 1.66M | 1.44M | 777K | 748K |
Add to Watchlist
Select watchlists to add or remove BCRX